| 吕海珍,高 华,栾 飞,陈 琳,程晓亮.利福布汀胶囊联合莫西沙星治疗耐多药肺结核的疗效及对炎性因子和T细胞亚群的影响[J].现代生物医学进展英文版,2020,(23):4576-4579. |
| 利福布汀胶囊联合莫西沙星治疗耐多药肺结核的疗效及对炎性因子和T细胞亚群的影响 |
| The Effect of Rifabutin Capsule Combined with Moxifloxacin in the Treatment of Multidrug Resistant Tuberculosis and Its Effect on Inflammatory Factors and T Cell Subsets |
| Received:May 08, 2020 Revised:May 31, 2020 |
| DOI：10.13241/j.cnki.pmb.2020.23.038 |
| 中文关键词: 利福布汀胶囊 莫西沙星 耐多药肺结核 疗效 炎性因子 T细胞亚群 |
| 英文关键词: Rifabutin capsule Moxifloxacin Multidrug resistant tuberculosis Efficacy Inflammatory factors T cell subsets |
| 基金项目:国家自然科学基金青年基金项目（81503010） |
|
| Hits: 652 |
| Download times: 412 |
| 中文摘要: |
| 摘要 目的：探讨利福布汀胶囊联合莫西沙星治疗耐多药肺结核的疗效及对炎性因子和T细胞亚群的影响。方法：选取2016年6月~2018年6月期间我院收治的耐多药肺结核患者110例，上述患者根据随机数字表法分为对照组（n=55）和研究组（n=55），对照组患者予以利福布汀胶囊联合左氧氟沙星治疗，研究组则给予利福布汀胶囊联合莫西沙星治疗，比较两组患者疗效、炎性因子和T细胞亚群水平，记录两组治疗期间不良反应发生情况。结果：研究组治疗12个月后、治疗18个月后病灶吸收率、空洞闭合率、痰菌转阴率均高于对照组（P<0.05）。两组治疗18个月后肿瘤坏死因子-α（TNF-α）、白介素-6（IL-6）、C反应蛋白（CRP）均较治疗前降低，且研究组低于对照组（P<0.05）。两组患者治疗18个月后CD4+/CD8+、CD4+较治疗前升高，且研究组高于对照组（P<0.05），CD8+较治疗前降低，且研究组低于对照组（P<0.05）。两组不良反应发生率比较无差异（P>0.05）。结论：利福布汀胶囊联合莫西沙星治疗耐多药肺结核，疗效显著，可有效改善炎性因子和T细胞亚群水平，且安全性较好，临床应用价值较高。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effect of rifabutin combined with moxifloxacin in the treatment of multidrug resistant tuberculosis and its effect on inflammatory factors and T cell subsets. Methods: From June 2016 to June 2018, 110 multidrug resistant tuberculosis patients in our hospital were selected. The patients were divided into control group (n = 55) and study group (n = 55) according to the random number table method. The patients in the control group were treated with rifabutin capsule combined with levofloxacin, while those in the study group were treated with rifabutin capsule combined with moxifloxacin. The curative effect, inflammatory factors and T cell subsets levels of the two groups were compared. The adverse reactions of the two groups were recorded during the treatment. Results: The absorption rate of focus, the rate of cavity closure and the negative rate of sputum bacteria in the study group at 12 months after treatment and 18 months after treatment were higher than those in the control group (P<0.05). 18 months after treatment, tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and C-reactive protein (CRP) were lower than those before treatment, and the study group was lower than control group (P<0.05). 18 months after treatment, CD4+/CD8+ and CD4+ in two groups were higher than those before treatment, and the study group was higher than those control group (P<0.05). CD8+ was lower than before treatment, and that in the study group was lower than that in the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: Rifabutin capsule combined with moxifloxacin is effective in the treatment of multidrug resistant tuberculosis. It can effectively improve the inflammatory factors and T cell subsets, and has good safety, and high clinical application value. |
|
View Full Text
View/Add Comment Download reader |
| Close |
